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arrhythmogenic right ventricular cardiomyopathy, and ion channelopathies, are the most prevalent causes of
sudden cardiac death in the U.S. Most of these cardiac abnormalities display intermittent EKG abnormalities.
An athlete may have an abnormal EKG without any family history, symptoms, or physical exam findings of a
cardiac abnormality. Could implementation of screening EKG with pre-participation physical exams for
athletes uncover these abnormalities, therefore decreasing the number of sudden cardiac deaths during
physical activity per year?
Hypothesis: An EKG can contribute to the pre-participation physical for athletes by detecting certain cardiac
abnormalities that lead to sudden cardiac death.
Study Design: Systematic review of medical trials.
Methods: Exhaustive search of databases including Ovid Medline, Pubmed, Cinahl, and Evidence-Based
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Results: Five studies were found that evaluated the correlation between abnormal EKGs in athletes and the
diagnosis of a cardiac abnormality that will cause sudden cardiac death. Only one study evaluated all
participants with an echocardiogram as well as an EKG. A likelihood ratio of 3.04, sensitivity of 73%, and
specificity of 76% was calculated using the information from this study.
Conclusion: Studies evaluated did not make a large impact on the diagnosis of hypertrophic cardiomyopathy
or other cardiac abnormalities by EKG. However, cardiac abnormalities that cause sudden cardiac death were
found with EKG alone, when history and physical exam findings were normal. EKGs should be incorporated
into pre-participation screenings to prevent sudden cardiac death.
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Abstract   
 
 
Background:  Current U.S. recommendations for pre-participation screening do not include EKG.  
European protocol recommends EKG as part of screening and Italy has followed this standard since 
1982.  Five cardiac abnormalities, hypertrophic cardiomyopathy, coronary artery anomaly of wrong 
sinus origin, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and ion channelopathies, 
are the most prevalent causes of sudden cardiac death in the U.S.  Most of these cardiac abnormalities 
display intermittent EKG abnormalities. An athlete may have an abnormal EKG without any family 
history, symptoms, or physical exam findings of a cardiac abnormality. 
Could implementation of screening EKG with pre-participation physical exams for athletes uncover 
these abnormalities, therefore decreasing the number of sudden cardiac deaths during physical activity 
per year?   
  
Hypothesis:  An EKG can contribute to the pre-participation physical for athletes by detecting certain 
cardiac abnormalities that lead to sudden cardiac death. 
 
Study Design:  Systematic review of medical trials 
 
Methods:  Exhaustive search of databases including Ovid Medline, Pubmed, Cinahl, and Evidence-
Based Medicine Review Multifile 
 
Results:  Five studies were found that evaluated the correlation between abnormal EKGs in athletes 
and the diagnosis of a cardiac abnormality that will cause sudden cardiac death.  Only one study 
evaluated all participants with an echocardiogram as well as an EKG.  A likelihood ratio of 3.04, 
sensitivity of 73%, and specificity of 76% was calculated using the information from this study. 
 
Conclusion:  Studies evaluated did not make a large impact on the diagnosis of hypertrophic 
cardiomyopathy or other cardiac abnormalities by EKG.  However, cardiac abnormalities that cause 
sudden cardiac death were found with EKG alone, when history and physical exam findings were 
normal. EKGs should be incorporated into pre-participation screenings to prevent sudden cardiac 
death. 
 
Keywords:  Sudden Cardiac death, mass screening, EKG, athletes 
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Can an EKG prevent sudden cardiac death in an athlete? 
A systematic review. 
 
Introduction 
 
As medical providers we all work to prevent death while improving quality of life.  Therefore, it is 
difficult to see a young athlete, allegedly in good health, die suddenly as it contradicts all efforts we 
work towards.  Witnessing this unforeseen event draws out the question, “how?” Young athletes are 
required to receive routine medical screening, however, it is possible for certain pathologies to be 
silent until a fatal event.  It seems as if there should be something the medical community should do to 
prevent the unforeseen theft of these lives. 
Sudden Cardiac Death (SCD) is an uncommon incident, only occurring in 0.61/100,000 persons per 
year in the U.S.1  By definition SCD is a death in which the patient had stable cardiac function until the 
event, and usually occurs less than one hour from symptom onset. 2 Corrado et al determined the 
relative risk of sudden cardiac death was 2.8 times greater for an athlete compared to their non-athlete 
counterparts.3  In the U.S. the top five cardiac abnormalities that cause SCD are, in order of 
prevalence, hypertrophic cardiomyopathy, coronary artery anomalies of wrong sinus origin, 
myocarditis, arrhythmogenic right ventricular cardiomyopathy, and ion channelopathies such as 
Brugada Syndrome and Long QT Syndrome1.  It is shown that hypertrophic cardiomyopathy accounts 
for 1/3 of SCD a year.  Other causes of SCD, including Wolf-Parkinson-White syndrome, Marfan 
Syndrome, cardiac sarcoidosis, blunt trauma to the chest, myxomatous mitral valve degeneration, 
premature atherosclerotic coronary artery disease, and aortic valve stenosis, will not be addressed in 
this paper. 
Once a provider comes to the diagnosis of a cardiac abnormality, recommendations of activity level 
must be provided.  The Bethesda Conference is a convention, sponsored by the American college of 
8 | P a g e  
 
Cardiology Foundation, in which representatives from various organizations, including cardiologists 
and other providers from the medical community, discusses the latest details of cardiovascular 
abnormalities in trained athletes.  All information is reviewed and recommendations of activity level 
according to diagnosis are formulated.  The U.S. as well as the European medical and athletic 
communities adheres to these guidelines. It is noted that these recommendations are specific for 
competitive athletes and not to be utilized with non-competitive recreational athletes.  Table 1 outlines 
the recommendations from the last conference, held in November 2004, for each of the top five 
diagnoses that have the potential to cause SCD. 
Hypertrophic Cardiomyopathy 
Hypertrophic Cardiomyopathy is an idiopathic disease of the heart that has a familial link.  It is 
considered an autosomal dominant disease that can also develop due to genetic mutations.  The left 
ventricle and/ or right ventricle develop asymmetrical hypertrophy without an obvious cause, like 
aortic stenosis.  The apical portion of the left ventricle is most often the hypertrophic portion.  Some 
patients will also have left ventricular stiffness and subsequent impaired filling.  Patients may be 
asymptomatic or complain of symptoms such as dyspnea, angina, fatigue, syncope, or palpitations. 
On physical exam one will find a harsh systolic crescendo-decrescendo murmur between the apex and 
left sternal border.  The murmur increases with the Valsalva maneuver or when standing from 
squatting, and decreases when squatting from standing, and with passive leg elevation, or handgrip.  
The murmur of hypertrophic cardiomyopathy is unlike the murmur of aortic stenosis, in that it does not 
radiate to the carotid arteries. It will, however, radiate to the lower sternal border, axillae, and to the 
base of the heart.  One may also note mild cardiomegaly, apical systolic thrill and heave, brisk carotid 
upstroke, or an S4 heart sound on physical exam. 
Electrocardiogram (EKG) may reveal left ventricular hypertrophy (LVH), ST and T-wave 
abnormalities, abnormal Q-waves, or atrial and ventricular arrhythmias. EKG is abnormal in 75%-95% 
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of patients with HCM.  Echocardiogram is considered the gold standard test to diagnose hypertrophic 
cardiomyopathy, and will reveal an asymmetrically hypertrophied septum, a narrow left ventricular 
outflow tract, a small to normal sized left ventricle, or systolic anterior motion of the mitral valve.4 
Treatment for hypertrophic cardiomyopathy is medical symptomatic treatment unless there is 
obstruction.  Alcohol ablation, myectomy, pacemaker, or implantable cardioverter-defibrillator (ICD) 
would be considered depending on the severity of the obstruction and success of less invasive 
treatment options.  It is recommended that digoxin be avoided unless atrial fibrillation develops or 
there is systolic dysfunction. 4 
Coronary artery anomalies of wrong sinus origin 
Coronary artery anomalies of wrong sinus origin are a congenital malformation of one of the coronary 
arteries.  The anomalous artery originates on the opposite side of the aorta than intended.  In the 
anomalous position the artery travels between the aorta and the pulmonary artery trunk.  This 
positioning creates an angling and a slit-like opening of the vessel, which decreases blood flow through 
the artery.4 
Patients may present with exertional syncope, chest pain, dizziness, or symptomatic ventricular 
arrhythmias.  Most often patients are asymptomatic, have normal EKGs, and no significant findings on 
physical exam.  Identification of anomalies can be done using MRI or ultrafast computed tomography 
imaging, but coronary arteriography is considered the best diagnostic study. 5Treatment for this 
malformation is surgical bypass. 
Myocarditis 
Myocarditis occurs most commonly from a viral infection (coxsackeivirus B), causing inflammation 
and necrosis of the myocardium, which also could implicate the endocardium, the pericardium, and the 
valves. Myocarditis may also result from adenovirus, parvovirus, drugs, or toxins like cocaine.  It is 
hypothesized that the viral infection triggers an immune response that subsequently injures the 
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myocardium after the virus has cleared.  Patients may present with symptoms of congestive heart 
failure, but most commonly are asymptomatic.  Symptoms such as chest pain dizziness, syncope, 
palpitations, tachyarrhythmias or bradyarrhythmias may appear days to weeks after a febrile illness.  
On physical exam the patient may exhibit tachycardia, hypotension, fever, murmur of mitral or 
tricuspid regurgitation, S3 or S4 gallops.  EKG abnormalities, such as ST segment and T-wave changes, 
conduction delays, left bundle branch block, AV block, supraventricular tachycardia, or ventricular 
ectopy are transient, and most often found in first 2 weeks of febrile illness.  An echocardiogram will 
often reveal regional wall motion abnormalities, mitral or tricuspid regurgitation.  Once the diagnosis 
is determined, serial echos will be closely scrutinized to determine progression of the disease. 
Erythrocyte sedimentation rate (ESR) will be elevated and may be used to monitor the course of the 
disease.  Creatinine phosphokinase-myocardial band (CPK-MB) and cardiac troponin-I (tn-I) may also 
be elevated.  Endomyocardial biopsy is the gold standard diagnostic test.  However, biopsy is not 
required since it does not contribute toward the treatment of myocarditis, unless it becomes necessary 
to make a more specific diagnosis should the patient fail to respond to standard therapy. Patients with 
symptomatic myocarditis should be hospitalized for symptom control.2 
Arrhythmogenic right ventricular cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy is another disease that is autosomal dominant.  In 
the disease process myocardial cells of the right ventricle are partially or totally replaced by adipose 
and fibrous tissue.  These changes lead to reentrant ventricular tachycardia which appears in the EKG 
as a left bundle branch block.  The EKG may also show inverted T-waves in right precordial leads and 
epsilon waves.  Further imaging may reveal right ventricular dilation and poor contractility with a 
normal left ventricle.  The diagnostic test of choice is MRI.4 
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Patients may experience palpitations or syncope, which can be treated with antiarrhymics.  However, if 
medications do not control symptoms, cryo-based or catheter-based radiofrequency ablation, ICD, or 
transplant must be considered. 
Ion channelopathies 
Ion channelopathies consist of a multitude of arrhythmic disorders, however, only two, Long QT 
Syndrome and Brugada Syndrome, are in the top five causes of sudden cardiac death. Long QT 
Syndrome may be idiopathic or acquired.  The idiopathic type has a familial link and genetic mutations 
that affect the potassium and sodium channels.  These mutations can occur on one or more of the five 
cardiac ion-channel genes, LQT1, LQT2, LQT3, LQT 5, and LQT6.  There is believed to be a 
correlation between swimming and ventricular arrhythmias in LQT1.  It is also found that LQT3 
patients are at a greater risk for arrhythmias during rest. 6The prolonged QT segment is considered 
long when corrected QT is longer than 0.46 sec for males and 0.48 sec for females.  Arrhythmias occur 
with adrenergic stimulation or may be induced by Valsalva Maneuver.  Long QT can progress to T-
wave alternans and ventricular tachycardia.  The cardiac exercise stress test is considered the 
diagnostic test of choice.  Some patients may present with syncope from the Torsade de pointes.  If a 
patient has a family history of sudden cardiac death or symptoms, a beta-blocker is recommended at 
maximum doses.  If the patient has a personal history of aborted sudden cardiac death ICD is 
recommended.  A pacemaker or left-sided cervicothoracic sympathetic ganlionectomy are also 
treatment options depending upon the success of beta-blockers.  Even with these treatments in place 
the Bethesda Conference recommends exclusion from all competitive sports. 
Brugada Syndrome is the second type of ion channelopathy that is a common cause of sudden cardiac 
death.  It is considered an autosomal dominant disease that has higher prevalence in Asian males. An 
EKG may show a right bundle branch block (RBBB) with ST elevation in anterior precordial leads V1-
V3.  However, these EKG findings which are the trademark pattern for Brugada Syndrome may be 
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intermittent.  The diagnostic test of choice is electrophysiological testing.  It is shown that the severity 
of the symptoms, such as syncope, correlates with the risk of sudden cardiac death.  Hyperthermia is 
noted to elicit the typical Brugada Syndrome EKG pattern, predisposing patients to fever-induced 
polymorphic ventricular tachycardia.  Treatment for Brugada syndrome is ICD. 
Athletes Heart 
An athlete who has rigorous training will experience structural cardiac remodeling to accommodate the 
physical activity of the body.  These structural changes may look similar to hypertrophic 
cardiomyopathy, but are considered physiologic left ventricular hypertrophy.  EKG abnormalities are 
present in 40% of elite athletes. 6  Increase in vagal tone may cause bradycardia, sinus arrhythmias, 
sinoatrial block, multifocal atrial rhythms, junctional rhythms, first-degree AV block, Mobitz type I 
second-degree AV block, biphasic or inverted T-waves, or ST depression.  All of these abnormalities 
will disappear with exercise. EKG may also reveal a notched p-wave, an increased R-wave or S-wave 
voltage, Q-waves, or repolarization abnormalities. Holter monitor may show frequent and/or complex 
ventricular tachyarrhythmias, which are consistent with myocarditis.  Increased left ventricular wall 
thickness, enlarged ventricular and atrial cavity dimension, and increased calculated cardiac mass may 
appear on echocardiogram.  Using echocardiography, a ‘grey zone’ is identified as the cardiac 
characteristics that are not completely diagnostic for HCM, dilated cardiomyopathy, or changes of an 
athlete’s heart.  The grey zone is defined as left ventricular wall thickness of 13-15mm and/or left 
ventricular cavity enlargement ≥ 60mm. These findings make the definitive diagnosis of HCM in an 
athlete difficult. Further testing such as genotyping or MRI can result in a diagnosis.  It is hypothesized 
that hypertrophy typical of an athlete’s heart does not do so at expense of the end diastolic left 
ventricular size, dilation of the left ventricle due to HCM is typically seen in end-stage HCM.  It is also 
recommended that the athlete decondition for about 12 weeks with subsequent reevaluation. If, after 
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deconditioning, the cardiac changes show patterns of normalization, it can be deduced that the athlete 
has neither HCM nor dilated cardiomyopathy.26  
Current Recommendations and the Italian Experience 
The American Heart Association (AHA) recommends a full evaluation prior to initial participation in a 
sport and to be repeated every two years for high school athletes, and every year for college athletes.  
A full evaluation consists of a 12-element screening survey that includes personal medical history and 
family medical history accompanied by a full physical exam. If one or more elements are positive, the 
AHA recommends further cardiovascular evaluation. The screening survey is comprised of the 
following points:  
 Personal history of   
1. Exertional chest pain or discomfort 
2. Unexplained Syncope or near-syncope  
3. Excessive exertional and unexplained dyspnea/fatigue, associated with exercise 
4. Prior recognition of a heart murmur 
5. Elevated systemic blood pressure 
 Family history of:  
6. Premature death (sudden and unexpected or otherwise) before age 50 years due to heart 
disease in ≥ 1 relative 
7. Disability from heart disease in a close relative < 50 years of age 
8. Specific knowledge of certain cardiac conditions in family members: hypertrophic or dilated 
cardiomyopathy, long-QT syndrome or other channelopathies, Marfan Syndrome, or clinically 
important arrhythmias 
 Physical Exam: 
9. Heart murmur 
10. Femoral pulses to exclude aortic coartation 
11. Physical stigmata of Marfan syndrome 
12. Brachial artery blood pressure in sitting position 
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This 12-element survey is essentially unchanged from the 1996 screening recommendations in spite of 
the fact that the in 2004/2005 the European Society of Cardiology and International Olympic 
Committee recommended EKGs as a part of preparticipation screening.7  It was determined that at a 
cost of 20 Euros for a history and physical examination a provider can include an EKG as part of the 
screening for a total of 30 Euros.  The athlete or athletic team would be responsible for the cost and 
athletes under the age of 18 would provide payment through the National Health System.8  Should the 
EKG be abnormal the patient would be referred for further cardiac evaluation.  Table II includes the 
parameters of an abnormal EKG. 
Many researchers have followed the Veneto Region of Italian athletic population due to the 
implementation of EKGs as part of the sports screening in 1982.  It is a state subsidized protocol.  Italy 
is well-equipped to meet these requirements because there has been an abundance of physicians 
specialized in sports medicine.  All physicians who will perform pre-participation screenings are 
required to have a post-graduate residency in sports medicine and sports cardiology.  This allows 
medical centers to exist in which the sole purpose is to evaluate athletes.8 Corrado determined that 
after the standardization of EKGs with pre-participation physicals the prevalence of SCD due to HCM 
decreased.  When compared with the non-athlete population it was noted that the prevalence of HCM 
did not decrease, only the SCD outcome in the athlete population decreased.  Of 269 Italians under the 
age of 35 who died of sudden cardiac death during the year 1979 – 1996, 49 athletes and 220 non-
athletes died.  Only one of the athletes died as a result of HCM, opposed to 16 non-athlete deaths due 
to HCM.  Arrhythmogenic right ventricular cardiomyopathy is now considered the most prevalent 
cause of SCD in Italy.9 Corrado performed another study examining the trends of SCD in Italy prior to 
standardized screening in 1979-1981, during early screening in 1982-1992, and throughout late 
screening 1993-2004.  He concluded that the incidence of SCD in athletes aged 12-35 years old 
decreased overall by 89%. 10  
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The AHA explains that, legally requiring an EKG as part of a preparticipation physical would be a 
strain on the U.S. healthcare system’s finances and resources. However, if most of the causes of 
sudden cardiac death are silent until fatal, can a provider identify them with history and physical 
alone?
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Methods 
 
An exhaustive database search was performed using terms: sudden cardiac death, screening, EKG, and 
pre-participation physical.  Databases used were Ovid Medline, Pubmed, Cinahl, and Evidence-Based 
Medicine Review Multifile.  From these results trials written in English were selected and reviewed to 
identify if the subjects were athletes, whether EKGs were used as a screening test, and if an outcome of 
hypertrophic cardiomyopathy, anomalous coronary artery origin, myocarditis, arrhythmogenic right 
ventricular cardiomyopathy, or ion channelopathy was identified.  Case studies and post mortem 
studies were eliminated. Each trial was critically appraised to determine validity.  Table III outlines the 
relevance of each trial to the evaluation of EKGs in diagnosing cardiac abnormalities during pre-
participation physicals. Two articles: “Cardiovascular pre-participation screening of young competitive 
athletes for prevention of sudden death in China” and “Prospective screening of 5,615 high school 
athletes for risk of sudden cardiac death” were eliminated since neither trial identified the number of 
athletes with a final diagnosis of the top five cardiac pathologies that could cause sudden cardiac death. 
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Results 
 
Five trials were found to adhere with all specifications of this review.  Table IV outlines each study 
and the corresponding outcomes. 
In the first trial evaluated, Antonio Pelliccia et al #1 evaluated the long term outcomes of abnormal 
EKGs in Italian athletes in a cohort study.  Specifically he addressed, abnormal EKGs with deeply 
inverted T-waves (≥ 2mm in at least 3 leads) in athletes who had follow-up with serial EKGs and 
echocardiogram for 9 ± 7 years and had no current diagnosis of structural heart disease.  These 81 
athlete’s clinical courses were compared with 229 controls with normal EKGs.  All subjects enrolled in 
the trial received an EKG and an echocardiogram. Eleven subjects of the abnormal EKG group were 
diagnosed with a cardiac disorder. In spite of a normal EKG four subjects were diagnosed with a 
cardiac disorder using echocardiogram.  Seventy of the subjects with abnormal EKGs and 225 subjects 
with normal EKGs were determined to have normal cardiac function. Five athletes with abnormal 
EKGs were diagnosed with a hypertrophic, dilated, arrhythmogenic right ventricular cardiomyopathy.  
The clinical features of cardiomyopathy did not develop until 12 ± 5 years into follow-up.  One of 
those five athletes died at the age of 24 due to arrhythmogenic right ventricular cardiomyopathy. No 
one in the control group developed cardiac symptoms nor was anyone diagnosed with cardiomyopathy. 
During the follow-up period, 27 of the subjects had normalization or decrease in abnormalities of their 
EKGs.  11 When compared with the gold standard test (echocardiogram) the calculated likelihood ratio 
is 3.04, providing a sensitivity of 73% and specificity of 76%. 
MG Wilson et al performed a study evaluating the benefit of 12-lead EKG with personal history, 
family history, and physical exam to screen for diseases that may cause sudden cardiac death.  The MG 
Wilson trial evaluated the EKGs of 1,074 national and international junior athletes and 1,646 
physically active schoolchildren.  All subjects were in the age range of 10-20 years old.  This 
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population represents a wide variety of ages and level of physical activity; however the type of sport in 
which each athlete participated was not specified.  In the trial, only those subjects with an abnormal 
EKG received further cardiovascular evaluation including an echocardiogram.   Diagnoses which were 
considered to increase risk of sudden cardiac death were: hypertrophic cardiomyopathy, long QT 
syndrome, Wolff-Parkinson-White syndrome, right ventricular outflow tract ventricular tachycardia, 
and arrhythmogenic right ventricular cardiomyopathy. The results of the study showed that, of the 
1,074 junior athletes screened, only 20 subjects had a positive personal or family history, 25 had an 
abnormal EKG, 45 required additional evaluations, and 5 were subsequently diagnosed with a cardiac 
disease that had the potential to cause sudden cardiac death.  Of the 1,646 schoolchildren 47 had a 
positive family or personal history, 15 had an abnormal EKG, 62 required further evaluation, and four 
were ultimately diagnosed with a cardiac disease that could lead to sudden cardiac death.  It is further 
explained that the nine subjects who were diagnosed with a cardiac disease all had abnormal EKG’s 
and no subject had a positive family or personal history.12 
Yuji Tanaka et al evaluated the usefulness and cost-effectiveness of a screening system using EKG in 
Japan compared to the US studies.  Over an eight year period all seventh and tenth graders in 
Kagoshima, Japan, were screened with EKG and a medical history questionnaire.  Only subjects with 
abnormal EKGs or a positive family history received further cardiac evaluation.  Subjects were re-
evaluated 3 years later. Of the original 68,503 students who underwent primary screening 30,696 had 
moved out of the area and were unavailable for follow-up.  The remaining 37,807 were followed for 
six consecutive years.  632 students were previously diagnosed with heart disease prior to this study 
and eliminated.  1,876 students had abnormal EKGs requiring further diagnostic studies, 1,370 of 
whom were found not to have any cardiac abnormalities and 497 of whom were considered to be at 
low-risk.  Nine students were diagnosed with high-risk diseases such as hypertrophic cardiomyopathy, 
left ventricular dilation, Wolff-Parkinson-White syndrome, primary pulmonary hypertension, and long 
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QT syndrome with torsade de pointes.  None of the subjects diagnosed with hypertrophic 
cardiomyopathy had a positive family history. Three of these nine subjects were athletes.  One of the 
high-risk subjects who was disqualified from his sport died at the age of 14 due to sudden cardiac 
death while jogging.  Two subjects in the low-risk group, each with normal EKGs, died during athletic 
activities due to sudden cardiac death.  13 
Antonio Pelliccia #2 also evaluated the efficiency of the Italian screening program for diagnosing 
hypertrophic cardiomyopathy.  A group of 4,485 elite Italian athletes were evaluated in this study 
within two to eight months of initial screening.  Through the standard screening each subject was 
determined not to have a diagnosis of HCM, and each subject underwent the gold standard exam of 
echocardiogram when diagnosing HCM.  If needed the subject had cardiac magnetic resonance 
imaging, coronary angiography, myocardial biopsy, electrophysiological study with programmed 
ventricular stimulation, or genetic testing. In this study, 37 athletes were found to have physiological 
left ventricular hypertrophy, consistent with the changes of in athlete’s heart.  Of these 37 athletes 28 
had abnormal EKGs.  Two athletes had left ventricular dimensions that were consistent with the typical 
athlete’s heart changes and non-obstructive HCM.  Two athletes were later diagnosed with HCM.  Of 
these four athletes, three had abnormal EKGs, however, it is unclear which subjects had abnormal 
EKGs.  Four athletes were diagnosed with myocarditis, three with mitral valve prolapse, two with 
Marfan syndrome, two with aortic valve disease, and 1 with arrhythmogenic right ventricular 
cardiomyopathy. 14 
Basavarajaiah et al evaluated 3,500 elite British athletes and the diagnosis of HCM.  Asymptomatic 
athletes aged 14-35 years were evaluated with EKG and echocardiogram.  All athletes had a negative 
family history for HCM and were involved in a variety of sports.  Fifty-three of these athletes were 
found to have a left ventricular wall thickness of greater than 12 mm, indicating left ventricular 
hypertrophy. Echocardiogram testing revealed three athletes had a nondilated left ventricle, which may 
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be consistent with HCM, and EKG abnormalities including deep T-wave inversion in inferior and/or 
lateral leads, however, other features of HCM were not present and all further cardiac tests were all 
negative.  One athlete underwent detraining for three months at which time echocardiogram and EKG 
abnormalities normalized.  The other two athletes in question underwent genetic testing which was 
negative for HCM.  Cardiac abnormalities other than HCM were diagnosed as result of this trial, six 
had WPW, nine had Long QT syndrome, five had mitral valve prolapse, two had atrial septal defect, 
three had bicuspid aortic valve, and one had a cortriatriatrum.  Twenty participants diagnosed with 
LVH also had deep T-wave inversion on EKG.  Fifteen subjects had deep T-wave inversion in the 
absence of LVH.  It is not stated if any of the group with normal echocardiograms had abnormal 
EKGs.15 
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Discussion 
 
It is shown that most of the pathologies that cause SCD will have an EKG abnormality and may not 
have an abnormal history or physical exam.  Therefore, can an EKG contribute to a pre-participation 
physical?  Each study, although flawed, was able to diagnose a cardiac abnormality when using EKG 
in addition to history and physical. 
When evaluating the value of a diagnostic test, EKG, there is a standard formula to determine the 
likelihood ratio.  This calculated number indicates the importance and value of the test as a diagnostic 
tool.   There are also a series of questions about a diagnostic test trial that help determine the validity 
of the trial itself.  When evaluating each trial each question was addressed. 
1. Was the gold standard test, as well as the diagnostic test in question, also performed on 
each subject?  Were the clinicians evaluating each test blinded? 
2. Did the patient sample provide a variety of characteristics that will be applied in clinical 
practice? 
3. Was the decision to perform the gold standard test influenced by the results of the 
diagnostic test in question? 
4. Were the methods of the trial presented with detail so they could be reproduced at a later 
date? 
The likelihood ratio (LR) would then be calculated using the formula: LR= a/(a+c) ÷ b/(b+d), when a= 
subjects with a positive diagnostic test and confirmed diagnosis, b= subjects with a positive diagnostic 
test and no diagnosis, c= subjects with a negative diagnostic test, but a confirmed diagnosis using the 
gold standard test, d = subjects with a negative diagnostic test, and a confirmed absence of diagnosis 
using the gold standard test.  If the LR is > 10 or < 0.1, then the diagnostic test can cause large changes 
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in the pretest probability of the target disorder, resulting in a high post-test probability.  If the LR is 5-
10 or 0.1-0.2, then the trial can cause moderate changes.  If the LR is 2-5 or 0.2 to 0.5 the trial will 
cause small changes.  If the LR is < 2 or > 0.5, then the trial can cause tiny changes.  Finally, if the LR 
= 1.0, the trial will cause no change at all.  Using the known pre-test probability and the calculated LR 
one can extrapolate the post-test probability using a likelihood ratio nomogram.16 
Using the values from above a sensitivity and specificity of the diagnostic test can be calculated.  
Sensitivity= a/(a + c)  and specificity= d/(b+d).  Sensitivity is a measure of the number of patients who 
have a positive diagnosis and a positive test.  Specificity is a measure of the number of patients who 
have a confirmed absence of the diagnosis and a negative test.  If both sensitivity and specificity values 
are high, then the diagnostic test in question is considered to be a good one.15 
Out of the five studies reviewed only one, Pelliccia #1, actually leads to an effective measurable 
comparison between a gold standard test, echocardiogram, and EKG.  However, there is no pretest 
probability of HCM in athletes, since it is underreported, prohibiting a post-test probability calculation.  
The LR was calculated to be 3.04 indicating that these results will only make small changes in the 
prevalence of HCM in athletes. A sensitivity of 73% and specificity of 76% were calculated indicating 
EKG has a relatively high accuracy when evaluating for HCM. 
Three of the studies, Pelliccia #1, Pelliccia #2, and Basavarajaiah, gave echocardiogram to all 
participants, at least suggesting that a comparison number between the results might be possible and/or 
useful, but Pelliccia #2 and Basavarajaiah did not provide sufficient information to calculate a 
likelihood ratio.  Wilson and Tanaka did not give echocardiograms, which is clearly a questionable 
design flaw given that they purport to address whether the EKG would be a helpful tool when 
screening for a cardiac abnormality. Test results were also not accurately defined when reporting 
number of subjects diagnosed and correlation of number of subjects with abnormal EKGs. 
23 | P a g e  
 
In Tanaka two patients with normal EKGs died of SCD during athletic activities, but since no echos 
had been performed it is unclear as to whether the cause could have been detectable.  The Tanaka study 
was also questionable from another standpoint in that it began with an extremely large sample size 
(69,033 students) but subsequently lost 30,696 students to follow up due to relocation.  This extreme 
loss rate calls into question the validity of the study as there is no way to assess whether the relocated 
population was comprised of diagnostically significant subjects or how many of them died during 
sports activities. 
Most studies provided the parameters for which they considered an EKG abnormal.  However, Tanaka 
did not specify the study parameters.  This presents another complication when comparing studies as 
the criteria may have varied.  Replication of this study in the future is therefore made difficult.  
Extensive evaluation may not detect an underlying cardiac abnormality, as was shown in the Italian 
population where 10 of 55 sudden cardiac deaths were athletes who had been fully evaluated in 
response to a suspicious screening EKG, history, or physical exam.10   In the Tanaka study 2 subjects 
with normal EKGs died suddenly while playing sports and one athlete who was restricted from 
competition died while jogging recreationally.13 
It is important to consider the fact that some of the subjects diagnosed with cardiac abnormalities had a 
normal history and physical exam.  Had the current recommendation of history and physical alone 
been implemented no diagnoses would have been established and the subject may have experienced 
SCD.  All subjects in Pelliccia #1 were asymptomatic.  In the Wilson trial 67 subjects were referred for 
further cardiac evaluation due to a positive history or abnormal physical exam. Forty subjects were 
referred due to abnormal EKGs.  All nine athletes diagnosed with cardiac abnormalities were 
asymptomatic and had a negative family history of SCD, but all nine had an abnormal EKG.   
The U.S. via the AHA has determined that routine EKGs with pre-participation physicals is not a cost 
effective practice, but European countries in addition to some private entities routinely include EKG as 
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a screening tool to unearth cardiac abnormalities, and in the process preventing a number of sudden 
cardiac deaths.  It is important to note Corrado’s evaluation of trends in the Italian population over 26 
years found an overall decrease of SCD by 89%. 10 
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Conclusion 
 
It would be appropriate for the U.S. to follow the example of other countries in implementing the 
maximum effort possible into these screening processes and increasing accessibility to a greater 
number of athletes.  Even though it may not yet be feasible to require EKGs by legislation as it is in 
Italy, it should be employed as a guideline or recommendation. 
The results suggest that to include EKG with pre-participation physicals would have positive impact on 
the diagnosis of cardiac abnormalities that cause sudden cardiac death.  Although the studies reviewed 
are too vague to be conclusive.  This is an area that requires further study with trials that compare 
echocardiogram with EKG in all of the participants, follow-up subjects closely, and report exact results 
of each group.
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Table 1. Presentation and recommendations for structural cardiac abnormalities 
Diagnosis Symptoms Physical 
Exam 
Findings 
EKG Findings Gold Standard 
Test 
36th Bethesda 
Recommendations6 
1. Hypertrophic 
Cardiomyopathy 
-Asymptomatic 
-dyspnea 
-angina 
-fatigue  
-syncope  
-palpitations 
-harsh systolic 
crescendo-
decrescendo 
murmur 
between the 
apex and left 
sternal border 
increasing 
with Valsalva 
Maneuver 
 
- mild 
cardiomegaly 
 
 -apical 
systolic thrill 
and heave 
 
-brisk carotid 
upstroke 
 
- S4 heart 
sound 
-LVH 
 
- ST and T-wave 
abnormalities  
 
-abnormal Q-
waves in inferior 
and/or lateral 
leads 
 
-atrial 
arrhythmias  
 
   and/or 
 
-ventricular 
arrhythmias 
Echocardiogram Exclusion from 
competitive sports, 
with possible 
exception of low 
intensity (class IA) 
2. Coronary 
artery anomalies 
of the wrong 
sinus origin 
-exertional 
syncope 
-chest pain  
-dizziness 
normal -normal 
 
-arrhythmias 
Coronary 
arteriography 
-Exclusion from all 
competitive sports 
until three months after 
successful bypass, if 
no evidence of 
ischemia, ventricular 
or tachyarrhythmias, or 
dysfunction during 
maximal exercise 
testing 
 
-if previous myocardial 
infarction follow 
recommendations for 
coronary artery disease 
Myocarditis -Asymptomatic 
-chest pain  
-dizziness  
-syncope 
-palpitations 
-tachycardia 
-hypotension 
-fever  
-murmur of 
mitral or 
-ST segment 
changes 
- T-wave 
changes 
-conduction 
Biopsy -Withdraw from 
competitive sports for 
six months after onset 
of clinical presentation 
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-shortness of 
breath  
-peripheral 
edema 
tricuspid 
regurgitation  
- S3 or S4 
gallops 
delays 
- left bundle 
branch block -
AV block  
-supraventricular 
tachycardia 
-ventricular 
ectopy 
-May return to sports 
once inflammatory and 
heart failure serum 
markers, EKG, LV 
function, wall motion, 
cardiac dimensions, 
and holter monitor 
readings have 
normalized 
Arrhythmogenic 
right ventricular 
cardiomyopathy 
-Palpitations 
-syncope 
 -ventricular 
tachyarrhythmias 
-LBBB 
-T-wave 
inversion in 
precordial leads 
V1-V3 
-epsilon waves 
Cardiac MRI Exclusion from 
competitive sports 
except low intensity 
sports (class IA) 
Ion 
Channelopathies: 
a) Long QT 
syndrome  
-Asymptomatic 
-syncope 
 -QTc ≥ 0.46 sec 
for males and ≥ 
0.48 sec for 
females 
 
-Torsade de 
pointes 
 
-Bifid or 
biphasic T-wave 
in all leads 
Exercise stress 
testing 
-Restriction to class IA 
sports if history of out-
of-hospital cardiac 
arrest or suspected 
long QT precipitated 
syncope 
 
-Restriction to class IA 
sports if asymptomatic 
with baseline QT 
prolongation 
 
-No restrictions for 
genotype-
positive/phenotype-
negative long QT 
syndrome patients 
 
-Restriction from 
competitive swimming 
for patients with LQT1 
 
-Restriction from 
contact sports if patient 
has an ICD/pacemaker 
due to risk of damage 
to pacemaker system 
 
-Restriction to class IA 
if ICD present 
Ion -Asymptomatic  -Right bundle Electrophysiolo Restriction to class IA 
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Channelopathies: 
b) Brugada 
syndrome 
-syncope branch block 
(RBBB) with ST 
elevation in 
anterior 
precordial leads 
V1-V3 
-inverted T-wave 
in precordial 
leads 
-ST up sloping 
coved type in 
right precordial 
leads 
gical testing sports, even if ICD 
present 
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Table II. Criteria for positive 12-Lead EKG8 
EKG Interval EKG Finding Diagnosis 
P-wave 
 
Negative portion of the P-
wave in lead V1 ≥ 0.1 mV in 
depth and ≥ 0.04s in duration 
Left atrial enlargement 
 Peaked P-wave in leads II and 
III or V1 ≥ 0.25 mV in 
amplitude 
Right atrial enlargement 
QRS Complex Right ≥ + 120o or left – 30o to 
-90o 
Frontal plane axis deviation 
 Amplitude of R or S wave in 
standard lead ≥ 2mV, S-wave 
in lead V1 or V2 ≥ 3mV, or R 
wave in lead V5 or V6 ≥ 3mV 
Increased voltage 
 Abnormal Q-waves ≥ 0.04s in 
duration or ≥ 25% of the 
height of the ensuing R wave 
or QS pattern in 2 or more 
leads 
Q-wave 
 QRS duration ≥ 0.12s 
R or R’ wave in lead V1 ≥ 
0.5mV in amplitude and R/S 
ratio ≥1 
Right or Left bundle branch 
block 
ST-segment, T-waves, and 
QT interval 
ST-segment depression or T-
wave flattening or inversion in 
2 or more leads 
 
 Prolongation of heart rate 
corrected QT interval > 0.44s 
in males and >0.46s in females 
Long QT Syndrome 
Rhythm and conduction 
abnormalities 
Premature ventricular beat 
(PVC) or more severe 
arrhythmias 
 
 Supraventricular tachycardia, 
atrial flutter, or atrial 
fibrillation 
 
 Short PR interval (<0.12s) 
with or without ‘delta’ wave 
Wolff-Parkinson-White 
Syndrome 
 Sinus bradycardia with resting 
heart rate ≤ 40bpm, 
PR ≥ 0.21s 
First, second, or third 
atrioventricular block 
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Table III. Trial Matrix 
Author/  Title/ 
Journal 
Yr.  
publi
shed 
Patients/  
Population 
Interve
ntion 
Comparison Outcome Study 
type 
Pelliccia/ 
Outcomes in 
athletes with 
marked ECG 
repolarization 
abnormalities/ 
The New England 
Journal of 
Medicine 
2008 Athletes during 
the years 1979-
2001 who had 
repolarization 
abnormalities 
and control 
group of athletes 
during 1980-
2000 who had 
normal EKGs 
EKG Echocardiogram Cardiac 
abnormality 
diagnosis 
Cohort 
Wilson/ 
Efficacy of 
personal symptom 
and family history 
questionnaires 
when screening for 
inherited cardiac 
pathologies: the 
role of 
electrocardiograph
y/ 
British Journal of 
Sports Medicine 
2007 Athletes and 
active 
schoolchildren 
under age 35 
EKG Cardiac 
evaluation if 
abnormal EKG 
Cardiac 
abnormality 
diagnosis 
Prospecti
ve  
Tanaka/ 
Usefulness and 
cost effectiveness 
of cardiovascular 
screening of young 
adolescents/  
Medicine and 
Science in Sports 
and Exercise 
2005 7th and 10th 
graders in 
Kagoshima, 
Japan during 
1989-1997 
EKG Cardiac 
evaluation if 
abnormal EKG 
Cardiac 
abnormality 
diagnosis 
Prospecti
ve 
Pelliccia/ 
Evidence for the 
efficacy of the 
Italian national 
pre-participation 
screening 
programme for 
identification of 
hypertrophic 
2006 Elite Italian 
athletes 
EKG Echocardiogram Cardiac 
abnormality 
diagnosis 
Prospecti
ve 
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cardiomyopathy in 
competitive 
athletes/ 
European Heart 
Journal 
Basavarajaiah/ 
Prevalence of 
hypertrophic 
cardiomyopathy in 
highly trained 
athletes/ 
Journal of the 
American College 
of Cardiology 
2007 Asymptomatic 
elite athletes 
from 1996-2006 
EKG Echocardiogram HCM 
diagnosis 
Prospecti
ve 
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Table IV. Trial Results 
 
(Parentheses) indicates total number of subjects diagnosed with a cardiac abnormality 
 
Trial Numbe
r of 
subject
s in 
Trial 
Number of 
subjects with 
abnormal 
EKG 
Hypertrophic 
Cardiomyopat
hy 
Coronar
y Artery 
Anomali
es of 
Wrong 
Sinus 
Origin 
Myocardit
is 
Arrhythmoge
nic Right 
Ventricular 
Cardiomyopat
hy 
Ion 
Channelopathi
es: Long QT 
Syndrome or 
Brugada 
Syndrome 
Pellicci
a #1 
310 81 (11) 3 diagnoses, 
including 1 
aborted sudden 
cardiac death 
NA NA 1 Fatality NA 
Wilson 2720 40 (9) 0 NA NA 1 3 
Tanaka 37,807 1,876 (9) 5 including 1 
sudden cardiac 
death 
NA NA NA 1 
Pellicci
a # 2 
4,450 31 (14) 2 NA 4 1 NA 
Basavar
ajaiah 
3,500 35 (26) 0 NA NA NA 9 
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